NCT04920734终止不适用
Description of Therapy Options and Successes in the Long-term Course of Delirium in the Recovery Room - Multicenter Observational Study (CESARO-2)
适应症
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 入组人数
- 5
- 试验地点
- 1
- 主要终点
- Morbidity
研究概览
简要总结
This project is a multicenter pilot project to evaluate the therapeutic success in the long term up to 3 months after a delirium in a recovery room. There is a Europe-wide recommendation for the prevention of postoperative delirium in older patients and the evidence and consensus-based guideline "Management of delirium, analgesia and sedation in intensiv care medicine" of the AWMF (Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften) are regularly updated for the detection and treatment of delirium in the intensive care unit. The aim is to evaluate the effects of a systematic delirium screening and the delirium treatment options in the long term in the same way as the current recommendations for the patient cohort of the recovery room.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •All patients admitted to the recovery room who have been diagnosed with delirium according to the treating physicians
- •The patient is on a ward in the hospital
- •Age ≥ 18 years
- •Stay in the recovery room ≥ 1 day
- •The patient is able to give consent
排除标准
- •Participation in a prospective intervention study (except adjuvant therapy study)
- •Patients with underlying neurological diseases that make it difficult to differentiate from delirium
- •Missing contact 3 months after stay in the recovery room.
结局指标
主要结局
Morbidity
时间窗: Up to three months
Postoperative complications according to Clavien-Dindo classification
次要结局
- Measurement of butyrylcholinesterase(Time until discharge from recovery room, an expected average of 5 days)
- Treatment of vegetative symptoms(Time until discharge from recovery room, an expected average of 5 days)
- Treatment of postoperative vomiting(Time until discharge from recovery room, an expected average of 5 days)
- Duration of delirium(Time until discharge from recovery room, an expected average of 5 days)
- Preventive measures against delirium 1(Time until discharge from recovery room, an expected average of 5 days)
- Preventive measures against delirium 2(Time until discharge from recovery room, an expected average of 5 days)
- Chronic comorbid diseases(Time until discharge from hospital, an expected average of 7 days)
- Treatment of pain(Time until discharge from recovery room, an expected average of 5 days)
- Treatment of productive psychotic symptoms(Time until discharge from recovery room, an expected average of 5 days)
- Number of participants with changes in laboratory values(Time until discharge from hospital, an expected average of 7 days)
- Anticholinergic drugs(Time until discharge from hospital, an expected average of 7 days)
- Health related quality of life(Up to three months)
- Incidence of delirium(Time until discharge from recovery room, an expected average of 5 days)
- Treatment of delirium(Time until discharge from hospital, an expected average of 7 days)
- Measurement of acetylcholinesterase(Time until discharge from recovery room, an expected average of 5 days)
- Treatment of sleep disorders(Time until discharge from recovery room, an expected average of 5 days)
- SOFA(Time until discharge from intensive care unit, an expected average of 6 days)
- Intensive care unit stay(Time until discharge from intensive care unit, an expected average of 6 days)
- Apache II(Time until discharge from intensive care unit, an expected average of 6 days)
- SAPS II(Time until discharge from intensive care unit, an expected average of 6 days)
- Treatment of anxiety(Time until discharge from recovery room, an expected average of 5 days)
- Hospital stay(Time until discharge from hospital, an expected average of 7 days)
研究者
Claudia Spies
Univ.- Prof. Dr. C. Spies
Charite University, Berlin, Germany
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Low Intensity Extracorporeal Shockwave Therapy for Patients With Erectile DysfunctionVasculogenic Erectile DysfunctionNCT02005731Initia58
Enrolling By Invitation
不适用
Outcomes of a Multidisciplinary Program for the Treatment of Chronic Pelvic PainChronic Pelvic Pain SyndromeNCT06317233Medstar Health Research Institute40
已完成
4 期
Study of Therapeutic Options for Subjects Discontinuing Efalizumab and Experiencing Disease RecurrencePsoriasisNCT01079988Merck KGaA, Darmstadt, Germany41
已完成
3 期
A Safety and Efficacy Study of Paclitaxel-eluting Balloon to Paclitaxel-eluting StentCoronary Instent RestenosisNCT01622075B. Braun Medical International Trading Company Ltd.220
Unknown
不适用
Evaluation of Morbidities, Endpoints and Reaching Targets in Diabetic Patients Managed by a Diabetes Specialist TeamObesityDiabetesNCT01690208Asia Diabetes Foundation600